Indiana University School of Medicine, Department of Urology, Indianapolis, Indiana.
Indiana University School of Medicine, Department of Urology, Indianapolis, Indiana.
Urol Oncol. 2020 Sep;38(9):739.e1-739.e8. doi: 10.1016/j.urolonc.2020.06.006. Epub 2020 Jul 6.
To investigate oncological outcomes and relapse patterns in retroperitoneal lymph node (LN)-only recurrences with salvage retroperitoneal lymph node dissection (S-RPLND).
We reviewed records of 19 patients undergoing RPLND for RCC recurrences between 2011 and 2018. All patients initially had primary non-metastatic RCC, with subsequent recurrence restricted to the retroperitoneal lymph nodes (LN). LN recurrence sites after nephrectomy and relapses after S-RPLND were assessed. The primary outcomes were post-RPLND Relapse-Free Survival (RFS), and Cancer-Specific Survival (CSS).
The median age of our cohort was 60 years at RPLND. Right and left nephrectomies were performed in 14 (73.7%) and 5 (26.3%), respectively. Clear cell carcinoma was found in 10 (52.6%) patients, followed by papillary in 4(21.1%), chromophobe in 2(10.5%), and 'other' in 3 (15.8%). The extent of lymphadenectomy during nephrectomy and S-RPLND varied based on surgical approach. The median follow-up time after S-RPLND of the entire cohort was 31.53 months, and the median RFS was 9.63 months. Overall, 4 patients died of cancer, of which 3 (75%) were N1 at time of nephrectomy. The CSS after RPLND at 3 and 5 years was 81.5% and 61.1%, respectively. The RFS after RPLND at 2 and 5 years was 44.4% and 29.6%, respectively.
Our results suggest that aggressive surgical management provides satisfactory CSS with acceptable complication rates. Moreover, we believe this subset of patients with node-only recurrence showed an unpredictable pattern of lymphatic spread, with predilection for regional dissemination warranting surgical resection of LN recurrences in a bilateral template fashion when feasible.
探讨挽救性腹膜后淋巴结清扫术(S-RPLND)治疗腹膜后淋巴结(LN)复发的肿瘤学结果和复发模式。
我们回顾了 2011 年至 2018 年间接受 RPLND 治疗肾细胞癌(RCC)复发的 19 例患者的记录。所有患者最初均患有原发性非转移性 RCC,随后复发仅限于腹膜后 LN。评估了肾切除术后的 LN 复发部位和 S-RPLND 后的复发情况。主要结局是 RPLND 后无复发生存期(RFS)和癌症特异性生存期(CSS)。
我们队列的中位年龄为 RPLND 时的 60 岁。14 例(73.7%)行右侧肾切除术,5 例(26.3%)行左侧肾切除术。10 例(52.6%)患者为透明细胞癌,其次是乳头状癌 4 例(21.1%)、嫌色细胞癌 2 例(10.5%)和“其他”3 例(15.8%)。肾切除术和 S-RPLND 期间的淋巴结清扫范围因手术方式而异。整个队列 S-RPLND 后的中位随访时间为 31.53 个月,中位 RFS 为 9.63 个月。总体而言,4 例患者死于癌症,其中 3 例(75%)在肾切除术时为 N1。RPLND 后 3 年和 5 年的 CSS 分别为 81.5%和 61.1%。RPLND 后 2 年和 5 年的 RFS 分别为 44.4%和 29.6%。
我们的结果表明,积极的手术治疗可提供令人满意的 CSS,且并发症发生率可接受。此外,我们认为,这组仅有淋巴结复发的患者表现出不可预测的淋巴扩散模式,区域播散倾向需要在可行的情况下以双侧模板方式切除 LN 复发。